SCHEMBL3324328

SCHEMBL3324328

COc1nc(N2CCC(C(=O)OC(C)(C)C)CC2)c(C#N)cc1C(=O)N(C)OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.45
KDM4E B2RXH2 7/20 0.45
P2RY12 Q9H244 7/20 0.45
CASP1 P29466 3/20 0.45
MAPK1 P28482 3/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 2/20 0.45
HTT P42858 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
CASP7 P55210 2/20 0.40
USP2 O75604 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2C9 P11712 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3329682 0.88 P2RY12 (0.49) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3223767 0.88 P2RY12 (0.49) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3234102 0.87 ALDH1A1 (0.47) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3226916 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3328653 0.84 P2RY12 (0.45) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3230375 0.84 P2RY12 (0.62) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL4996728 0.78 P2RY12 (0.38) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3220034 0.78 ALDH1A1 (0.53) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3226385 0.77 ALDH1A1 (0.52) ALDH1A1KDM4EP2RY12CASP1MAPK1
SCHEMBL3240706 0.76 P2RY12 (0.47) ALDH1A1KDM4EP2RY12CASP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137277-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS ASTRAZENECA AB (SE) 2010-06-03 US disclosed
EP-2111400-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. AstraZeneca AB (SE) 2009-10-28 EP disclosed
US-20080171732-A1 New Pyridine Analogues IX 519 ASTRAZENECA AB (SE) 2008-07-17 US disclosed
WO-2008085117-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. ASTRAZENECA AB (SE) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171732-A1 New Pyridine Analogues IX 519 P2RY12, P2RY11, P2RY1 ALDH1A1 1518/4885KDM4E 3186/4885P2RY12 1/4885
US-20100137277-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS P2RY12, P2RY11, P2RY1 ALDH1A1 1782/4885KDM4E 4200/4885P2RY12 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.